Imperial College London
Portrait Picture

DrHugoTurner

Faculty of Medicine, School of Public Health

Lecturer
 
 
 
//

Contact

 

+44 (0)20 7594 7120hugo.turner Website

 
 
//

Location

 

Office 411School of Public HealthWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Turner:2022,
author = {Turner, HC and Ottesen, EA and Bradley, MH},
journal = {Parasites and Vectors},
pages = {1--9},
title = {A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020)},
url = {https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05268-w},
volume = {15},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundLymphatic filariasis (LF), is a neglected tropical disease (NTD). In 2000 the World Health Organization (WHO) established the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A key component of this programme is mass drug administration (MDA). Between 2000 and 2020, the GPELF has delivered 8.6 billion treatments to at risk populations. The last impact assessment of the programme evaluated the treatments provided between 2000-2014.  The goal of this analysis is to provide an updated health impact assessment of the programme, based on the numbers treated between 2000-2020.MethodsWe updated and refined a previously established model that estimates the number of clinical manifestations and disability-adjusted life years (DALYs) averted by the treatments provided by the GPELF. The model comprises three different population cohorts that can benefit from MDA provided (those protected from acquiring infection, those with subclinical morbidity prevented from progressing and those with clinical disease alleviated). The treatment numbers were updated for all participating countries including using data from the WHO. In addition, data relating to the estimated number of individuals initially at risk of LF infection were updated where possible. Finally, the DALY calculations were refined to use updated disability weights.Results Using the updated model and corresponding treatment data, we projected that the total benefit cohort of the GPELF (2000-2020) would consist of approximately 58.5 million individuals and the programme would avert 44.3 million chronic LF cases. Over the lifetime of the benefit cohorts, this corresponded to 244 million DALYs being averted.Conclusion This study indicates that substantial health benefits have resulted from the first 20 years of the GPELF. It is important to note that the GPELF would have both additional benefits not quantified by the DALY burden metric as well as benefits on other co-endemic diseases (such as soil-transmi
AU  - Turner,HC
AU  - Ottesen,EA
AU  - Bradley,MH
EP  - 9
PY  - 2022///
SN  - 1756-3305
SP  - 1
TI  - A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020)
T2  - Parasites and Vectors
UR  - https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05268-w
UR  - http://hdl.handle.net/10044/1/96371
VL  - 15
ER  -
Download